←
Gad530 posts
Gad avatar

Gad

@gadmark

PhD candidate studying transport mechanisms at Rockefeller University

◷ Joined May 2011▧ 10 Photos and videos
Gad avatar
Gad@gadmark·Apr 17

Thrilled to share our new paper: SLC33A1 is the long-sought ER GSSG exporter, maintaining redox homeostasis in the ER. Huge congratulations to my co-first author @shanshanliu1218 and my PIs @KivancBirsoy and @HiteLabMSKCC for leading this work. nature.com/articles/s41556-0… 🧵 1/9

Toshitaka Nakamura avatar
⟳ Gad retweeted
Toshitaka Nakamura@ToshiNakamura51·Sep 15

1/ Excited to share our new paper in @NatMetabolism: cysteine excess triggers a mitochondrial iron-dependent cell death. nature.com/articles/s42255-0…

Kivanc Birsoy avatar
⟳ Gad retweeted
Kivanc Birsoy@KivancBirsoy·Sep 15

Why is glutathione, rather than cysteine, the major cellular thiol? Our new work by @ToshiNakamura51 suggests unlike other amino acids, excess cysteine is intrinsically toxic to mammalian cells via mitochondrial iron accumulation. @RockefellerUniv nature.com/articles/s42255-0…

Bo Wang avatar
⟳ Gad retweeted
Bo Wang@BoWang87·Aug 20

Moderna/Merck just ran a 1,137-patient Phase 3 trial where every single dose was unique to that patient's tumor. It worked. The pipeline: surgical resection → whole exome + RNA sequencing → ML neoantigen ranking → mRNA encoding up to 34 patient-specific targets → manufactured and shipped in 8 weeks. One drug, different sequence for every patient. The ML step is worth to note: the algorithm ingests WES + RNA-seq to identify somatic mutations, then predicts which of those will actually be immunogenic, ie, displayed on tumor cell surface and trigger a T-cell response. It's designed to keep learning from accumulated clinical and immunogenicity data across patients, not just per-patient. INTerpath-001 (Stage IIB-IV resected melanoma, 2:1 randomized): combination with pembrolizumab beat Keytruda alone on both primary (RFS) and key secondary (DMFS) at interim. Phase 2b at ASCO 2026 showed 49% reduction in recurrence/death, 59% in distant metastasis/death at 5 years. Phase 3 confirmed both. What this validates: — tumor-specific neoantigen prediction by ML works in a blinded trial at scale — 8-week personalized mRNA manufacturing is operationally real — effect is additive on PD-1 blockade, not redundant This is first positive Ph3 for individualized neoantigen therapy. First positive Ph3 for any mRNA cancer therapeutic. What a great time to live in!! This is the best time for AI & biotech!

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma. Read more:

Post attachment
Shanshan Liu avatar
⟳ Gad retweeted
Shanshan Liu@shanshanliu1218·Apr 17

Excited to share our new work! We identified SLC33A1 as the major ER GSSG exporter that maintains redox balance in the ER lumen.

Our new work by @shanshanliu1218 and @gadmark addresses a fundamental question: how does ER maintain its unique oxidizing environment, while rest of the cell is reducing? Here, we identify SLC33A1 as the major ER GSSG exporter in mammalian cells. nature.com/articles/s41556-0…

Kivanc Birsoy avatar
⟳ Gad retweeted
Kivanc Birsoy@KivancBirsoy·Apr 17

Our new work by @shanshanliu1218 and @gadmark addresses a fundamental question: how does ER maintain its unique oxidizing environment, while rest of the cell is reducing? Here, we identify SLC33A1 as the major ER GSSG exporter in mammalian cells. nature.com/articles/s41556-0…

Brandon Chen, PhD avatar
⟳ Gad retweeted
Brandon Chen, PhD@BrandonTWChen·Apr 17

Check out this impressive work and #tweetorial from @gadmark and @shanshanliu1218! If you’re interested in organellar metabolism and metabolite transport, this is a landmark paper on ER redox metabolism and transport👇

Thrilled to share our new paper: SLC33A1 is the long-sought ER GSSG exporter, maintaining redox homeostasis in the ER. Huge congratulations to my co-first author @shanshanliu1218 and my PIs @KivancBirsoy and @HiteLabMSKCC for leading this work. nature.com/articles/s41556-0… 🧵 1/9

Alon Millet avatar
⟳ Gad retweeted
Alon Millet@AlonMillet·Apr 17

Was an honor to contribute to this tremendous study co-led by the brilliant duo of @gadmark and @shanshanliu1218. Check out the thread below to learn more about how SLC33A1 works to maintain ER redox balance!

Thrilled to share our new paper: SLC33A1 is the long-sought ER GSSG exporter, maintaining redox homeostasis in the ER. Huge congratulations to my co-first author @shanshanliu1218 and my PIs @KivancBirsoy and @HiteLabMSKCC for leading this work. nature.com/articles/s41556-0… 🧵 1/9

Gad avatar
Gad@gadmark·Apr 17

Loss of SLC33A1 shifts PDIs toward oxidized states, triggers ER stress, and creates dependency on ERAD. Disease variants linked to Huppke-Brendel syndrome impair GSSG export. This work connects ER redox biology to neurodegeneration and cancer. 8/9

Gad avatar
Gad@gadmark·Apr 17

Mutagenesis confirmed the structure. Individual Y225A or Y418A mutations partially impair transport, but the double mutant (2YA) fully phenocopies knockout — no GSSG clearance, full ER stress, no rescue from GSH overload lethality. 7/9

Post attachment
Gad avatar
Gad@gadmark·Apr 17

To understand GSSG dynamics in the binding site, we ran 3.4 microseconds of MD simulations. Thanks to @BelayViktor for leading this analysis. The simulations confirmed the extended binding pose and identified key contact residues. 6/9

Gad avatar
Gad@gadmark·Apr 17

We solved the cryo-EM structure of GSSG-bound SLC33A1. GSSG sits in an extended conformation deep in the central cavity, coordinated by aromatic residues. No strong ionic interactions — shape and aromaticity do the work. 5/9

Post attachmentPost attachment
Gad avatar
Gad@gadmark·Apr 17

We directly confirmed transport by reconstituting purified SLC33A1 into liposomes. Radiolabeled GSSG accumulated in a time-dependent manner in SLC33A1-containing liposomes but not in protein-free vesicles. SLC33A1 is a bona fide GSSG transporter. 4/9

Post attachment